Supernus Pharmaceuticals
SUPN
SUPN
246 hedge funds and large institutions have $1.44B invested in Supernus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 90 increasing their positions, 90 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
6% more funds holding
Funds holding: 233 → 246 (+13)
0.26% more ownership
Funds ownership: 91.68% → 91.94% (+0.26%)
0% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 90
Holders
246
Holding in Top 10
6
Calls
$10.5M
Puts
$9.47M
Top Buyers
| 1 | +$209M | |
| 2 | +$11.6M | |
| 3 | +$8.94M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.49M |
| 5 |
Axa
Paris,
France
|
+$6.52M |
Top Sellers
| 1 | -$16.3M | |
| 2 | -$13.6M | |
| 3 | -$8.89M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$8.76M |
| 5 |
Morgan Stanley
New York
|
-$5.03M |